MA44976A - Sélection directe de cellules exprimant des teneurs élevées en protéines hétéromères à l'aide de vecteurs de complémentation intragénique de glutamine synthétase - Google Patents

Sélection directe de cellules exprimant des teneurs élevées en protéines hétéromères à l'aide de vecteurs de complémentation intragénique de glutamine synthétase

Info

Publication number
MA44976A
MA44976A MA044976A MA44976A MA44976A MA 44976 A MA44976 A MA 44976A MA 044976 A MA044976 A MA 044976A MA 44976 A MA44976 A MA 44976A MA 44976 A MA44976 A MA 44976A
Authority
MA
Morocco
Prior art keywords
intragenic
supplementation
vectors
cells expressing
high levels
Prior art date
Application number
MA044976A
Other languages
English (en)
French (fr)
Inventor
Neeraj Jagdish Agrawal
Kristine M Daris
Yadlin Dina A Fomina
Randal R Ketchem
Jeffrey T Mcgrew
Trent P Munro
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA44976A publication Critical patent/MA44976A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y104/00—Oxidoreductases acting on the CH-NH2 group of donors (1.4)
    • C12Y104/01—Oxidoreductases acting on the CH-NH2 group of donors (1.4) with NAD+ or NADP+ as acceptor (1.4.1)
    • C12Y104/01002—Glutamate dehydrogenase (1.4.1.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/01—Acid-ammonia (or amine)ligases (amide synthases)(6.3.1)
    • C12Y603/01002—Glutamate-ammonia ligase (6.3.1.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/04—Other carbon-nitrogen ligases (6.3.4)
    • C12Y603/04004—Adenylosuccinate synthase (6.3.4.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/04—Other carbon-nitrogen ligases (6.3.4)
    • C12Y603/04005—Argininosuccinate synthase (6.3.4.5)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
MA044976A 2016-05-11 2017-05-11 Sélection directe de cellules exprimant des teneurs élevées en protéines hétéromères à l'aide de vecteurs de complémentation intragénique de glutamine synthétase MA44976A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662334966P 2016-05-11 2016-05-11

Publications (1)

Publication Number Publication Date
MA44976A true MA44976A (fr) 2019-03-20

Family

ID=58873869

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044976A MA44976A (fr) 2016-05-11 2017-05-11 Sélection directe de cellules exprimant des teneurs élevées en protéines hétéromères à l'aide de vecteurs de complémentation intragénique de glutamine synthétase

Country Status (17)

Country Link
US (2) US11384140B2 (enExample)
EP (2) EP4067493A1 (enExample)
JP (2) JP6972022B2 (enExample)
KR (2) KR102439719B1 (enExample)
CN (2) CN115873904A (enExample)
AU (2) AU2017263454B2 (enExample)
BR (1) BR112018073316A2 (enExample)
CA (1) CA3024027A1 (enExample)
CL (1) CL2018003210A1 (enExample)
EA (1) EA201892588A1 (enExample)
ES (1) ES2914118T3 (enExample)
IL (2) IL300591A (enExample)
MA (1) MA44976A (enExample)
MX (2) MX394682B (enExample)
SG (1) SG11201810040WA (enExample)
TW (2) TWI757291B (enExample)
WO (1) WO2017197098A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018093331A1 (en) * 2016-11-16 2018-05-24 Agency For Science, Technology And Research Attenuated glutamine synthetase as a selection marker
EP4119133A1 (en) 2017-05-24 2023-01-18 Thoeris GmbH Glutamine synthetase protein conjugate
CN109988777A (zh) * 2017-12-29 2019-07-09 南京金斯瑞生物科技有限公司 谷氨酰胺合成酶基因以及应用
WO2020227206A1 (en) * 2019-05-07 2020-11-12 Amgen Inc. Vectors and expression systems for producing recombinant proteins
US20250101402A1 (en) * 2021-08-03 2025-03-27 Shanghai Zhenge Biotechnology Co., Ltd. Selectable markers for eukaryotic expression system
EP4457348A4 (en) * 2021-12-27 2025-09-03 Shanghai Zhenge Biotechnology Co Ltd NEW MARKERS FOR RECOMBINANT PRODUCTION SYSTEM
AU2023238775A1 (en) 2022-03-23 2024-10-31 Boehringer Ingelheim International Gmbh Bacterial glutamine synthetase as selection marker in mammalian cells
EP4496884A1 (en) * 2022-03-23 2025-01-29 Boehringer Ingelheim International Gmbh New glutamine synthetase variants as selection marker
WO2025037708A1 (en) * 2023-08-16 2025-02-20 Korea Advanced Institute Of Science And Technology Method for selection of cell line expressing high levels of recombinant protein using glutamine synthetase split expression vector
WO2025128343A1 (en) 2023-12-11 2025-06-19 Just-Evotec Biologics, Inc. Protein expression using trans-splicing and split selectable markers
CN118006685B (zh) * 2024-04-07 2024-07-23 上海碧博生物医药科技有限公司 一种快速的高表达单克隆细胞株构建方法
WO2025250814A1 (en) * 2024-05-31 2025-12-04 Amgen Inc. Intein based split glutamine synthetase engineering

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JPH0819508B2 (ja) 1987-08-19 1996-02-28 三菱マテリアル株式会社 Ｆｅ−Ｃｏ基合金製高周波用磁芯材
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5624818A (en) 1991-09-09 1997-04-29 Fred Hutchinson Cancer Research Center Nucleic acids encoding regulatory proteins that dimerize with Mad or Max
CA2312667C (en) 1991-10-25 2002-11-19 Immunex Corporation Novel cytokine
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5573925A (en) 1994-11-28 1996-11-12 The Wistar Institute Of Anatomy And Biology P53 proteins with altered tetramerization domains
ES2214541T3 (es) 1995-06-07 2004-09-16 Immunex Corporation Muteina de cd40l.
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US6342345B1 (en) 1997-04-02 2002-01-29 The Board Of Trustees Of The Leland Stanford Junior University Detection of molecular interactions by reporter subunit complementation
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
EP1196566B1 (en) * 1999-07-12 2006-02-01 Genentech, Inc. Expression vectors and methods
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
GB0025144D0 (en) 2000-10-13 2000-11-29 Medical Res Council Concatenated nucleic acid sequences
JP4266825B2 (ja) * 2001-09-20 2009-05-20 イミユネツクス・コーポレイシヨン ヘテロマーポリペプチドを発現する細胞の選択
GB0200977D0 (en) 2002-01-17 2002-03-06 Lonza Biologics Plc Glutamine-auxotrophic human cells capable of producing proteins and capable of growing in a glutamine-free medium
WO2004038003A2 (en) * 2002-10-25 2004-05-06 Five Prime Therapeutics, Inc. Human polypeptides encoded by polynucleotides and methods of their use
US7384744B2 (en) * 2002-11-29 2008-06-10 Boehringer Ingelheim Pharma Gmbh & Co., Kg Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products
US20040202995A1 (en) 2003-04-09 2004-10-14 Domantis Nucleic acids, proteins, and screening methods
JP4751326B2 (ja) * 2003-09-04 2011-08-17 メダレックス インコーポレイテッド 発現ベクター
DK1797127T3 (en) 2004-09-24 2017-10-02 Amgen Inc Modified Fc molecules
US8053238B2 (en) 2005-10-31 2011-11-08 Unhwa Corporation Isolated population of plant single cells and method of preparing the same
US20070254338A1 (en) 2006-04-24 2007-11-01 Amgen Inc. Method for making recombinant protein using complementation dependent DHFR mutants
WO2008154014A2 (en) 2007-06-11 2008-12-18 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
US9234210B2 (en) * 2010-08-25 2016-01-12 Intrexon Ceu, Inc. Selectable markers and related methods
KR101890446B1 (ko) 2010-11-08 2018-08-21 제이씨알 파마 가부시키가이샤 신규 발현 벡터
WO2012095514A1 (en) 2011-01-14 2012-07-19 Vivalis Recombinant protein production system
US9133493B2 (en) 2011-04-21 2015-09-15 Amgen Inc. Method for culturing mammalian cells to improve recombinant protein production
AU2012203048A1 (en) * 2011-05-24 2012-12-13 Agency For Science, Technology And Research IRES mediated multicistronic vectors
KR101411740B1 (ko) * 2012-05-29 2014-06-27 한화케미칼 주식회사 항체 발현용 바이시스트로닉 발현벡터 및 이를 이용한 항체의 생산 방법

Also Published As

Publication number Publication date
JP2019514417A (ja) 2019-06-06
MX2018013882A (es) 2019-03-14
EP3455359A1 (en) 2019-03-20
IL300591A (en) 2023-04-01
MX2022009674A (es) 2022-09-09
AU2017263454B2 (en) 2023-02-09
MX394682B (es) 2025-03-24
IL262923B2 (en) 2023-08-01
TW202223093A (zh) 2022-06-16
JP6972022B2 (ja) 2021-11-24
BR112018073316A2 (pt) 2019-06-04
AU2023200660B2 (en) 2024-12-12
EA201892588A1 (ru) 2019-06-28
AU2023200660A1 (en) 2023-03-09
EP3455359B1 (en) 2022-03-09
TW201805422A (zh) 2018-02-16
US20230048658A1 (en) 2023-02-16
US20190127452A1 (en) 2019-05-02
IL262923B1 (en) 2023-04-01
KR102439719B1 (ko) 2022-09-02
ES2914118T3 (es) 2022-06-07
CN109219660B (zh) 2023-01-06
JP2022033734A (ja) 2022-03-02
WO2017197098A1 (en) 2017-11-16
KR20210135635A (ko) 2021-11-15
EP4067493A1 (en) 2022-10-05
IL262923A (en) 2019-01-31
JP7344949B2 (ja) 2023-09-14
CL2018003210A1 (es) 2019-02-15
CN115873904A (zh) 2023-03-31
KR20190005193A (ko) 2019-01-15
KR102323519B1 (ko) 2021-11-09
CN109219660A (zh) 2019-01-15
SG11201810040WA (en) 2018-12-28
TWI757291B (zh) 2022-03-11
CA3024027A1 (en) 2017-11-16
AU2017263454A1 (en) 2018-12-06
TWI821905B (zh) 2023-11-11
US11384140B2 (en) 2022-07-12

Similar Documents

Publication Publication Date Title
MA44976A (fr) Sélection directe de cellules exprimant des teneurs élevées en protéines hétéromères à l'aide de vecteurs de complémentation intragénique de glutamine synthétase
EP3294165A4 (en) METHOD FOR IMPLANTING A BONE SCREW
EP3390429A4 (en) MODIFIED CAPSID PROTEINS FOR IMPROVED DELIVERY OF PARVOVIRUS VECTORS
IL267623A (en) Protein drugs for the treatment of aging cells
SG11202006498PA (en) Methods of assessing transduction potency of viral vectors
DK3568483T3 (da) Polynukleotider og vektorer til ekspression af transgener
EP3350313A4 (en) DERIVATION OF LIVER ORGANOIDS FROM HUMAN PLURIPOTENTIAL STEM CELLS
DK3512543T3 (da) Trimerstabiliserende mutationer af hiv-kappeprotein
EP3371301A4 (en) METHOD AND COMPOSITIONS FOR INDUCING THE DIFFERENTIATION OF HEMATOPOIETIC CELLS
SG11202007621TA (en) Controlled expression of transgenes using close-ended dna (cedna) vectors
SG11202001941SA (en) Non-integrating dna vectors for the genetic modification of cells
EP3733242C0 (en) Radiation therapy quality assurance
IL260730B (en) Process for preparing terpinene-4-ol
EP3512567A4 (en) CELL-SPECIFIC EXPRESSION OF MODRNA
EP3548617A4 (en) OPTIMIZED LENTIVIRAL VECTOR FOR STEM CELL THERAPY OF HEMOGLOBINOPATHIA
ZA201708638B (en) Prrsv minor protein¿containing recombinant viral vectors and methods of making and use thereof
EP3436049A4 (en) ANGIOPOIETIN-SIMILAR PROTEIN 8 (ANGPTL8)
DK3432912T3 (da) Hsv-vektorer med høj transduktion
HUE064252T2 (hu) Antigénkötõ fehérjék töltött mélységi szûrése
EP3370755A4 (en) ACTIVATION OF RESIDENT MEMORY T CELLS FOR CANCER IMMUNOTHERAPY
IL260720B (en) Inhibitors of the orexin-1 receptor and compositions comprising the same
ZA201805452B (en) Use of herbicide-tolerant protein
EP3382929C0 (en) TECHNOLOGY FOR GENERATION OF SYMMETRICAL ENCRYPTION ALGORITHMS
ZA201903885B (en) Polymorphs of herbicidal sulfonamides
DK3414517T3 (da) Holografisk karakterisering af proteinaggregater